| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Behenamide does not have a defined pharmacological target. It has been shown to have physiological effects on atherosclerotic cardiovascular disease and fatty acid synthesis. It is a fatty acid amide that acts as an angiogenic agent; however, the mechanism of angiogenic activity is unknown and this lipid does not promote proliferation of endothelial cells or induce inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro studies have shown that Behenamide is a fatty acid amide that acts as an angiogenic agent. The mechanism of angiogenic activity is unknown. It has been studied for its physiological effects on atherosclerotic cardiovascular disease and fatty acid synthesis.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for Behenamide as a therapeutic agent. The compound is used as a biochemical reagent and surfactant. It is not administered to animals for pharmacological evaluation. Its applications are limited to in vitro biochemical research and industrial applications.
|
| Enzyme Assay |
For non-cellular assays, Behenamide is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound has a molecular weight of 339.60 and molecular formula C₂₂H₄₅NO. Storage: room temperature in a cool and dry place. The compound is a solid at room temperature.
|
| Cell Assay |
For in vitro cell-based studies, Behenamide can be used to assess effects on endothelial cell proliferation and angiogenic activity. Cells are cultured under standard conditions and treated with the compound to evaluate effects on angiogenesis and inflammatory markers. The compound is typically dissolved in appropriate solvents and diluted in cell culture medium. Appropriate controls should be included in the experimental design.
|
| Animal Protocol |
For in vivo animal studies, Behenamide is not typically administered as a test compound. It is used as a biochemical reagent and surfactant. If used in animal studies for specific research purposes, it would be administered via appropriate routes with suitable formulations. Standard animal welfare guidelines should be followed.
|
| ADME/Pharmacokinetics |
Behenamide has a molecular weight of 339.60 and molecular formula C₂₂H₄₅NO. Storage: keep in a cool, dry place protected from light and moisture. The compound is a solid at room temperature. Solubility: soluble in organic solvents. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Behenamide is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
Docosanamide is a fatty amide.
Behenamide (CAS 3061-75-4) is also known as docosanamide. It is a nonionic surfactant stable in acidic, alkaline and aqueous media. It is used as a slip agent, lubricant, and mold release agent in industrial applications and in personal care products as a thickener and emollient. No clinical trials or therapeutic approvals exist. |
| Molecular Formula |
C22H45NO
|
|---|---|
| Molecular Weight |
339.60
|
| Exact Mass |
339.35
|
| CAS # |
3061-75-4
|
| PubChem CID |
76468
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
471.1±13.0 °C at 760 mmHg
|
| Melting Point |
110 - 113 °C
|
| Flash Point |
238.7±19.8 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.460
|
| LogP |
9.39
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
24
|
| Complexity |
252
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCC(=O)N
|
| InChi Key |
ORAWFNKFUWGRJG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H45NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h2-21H2,1H3,(H2,23,24)
|
| Chemical Name |
docosanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9446 mL | 14.7232 mL | 29.4464 mL | |
| 5 mM | 0.5889 mL | 2.9446 mL | 5.8893 mL | |
| 10 mM | 0.2945 mL | 1.4723 mL | 2.9446 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
